The cytoplasmic tyrosine kinase Src has been implicated in signal transduction induced by growth factors and integrins. Src also shows oncogenic activity when deregulated. Accumulating evidence indicates that the tyrosine kinase Abl is an important substrate for Src signalling in normal cells. Here we show that Abl is also required for Src-induced transformation of mouse fibroblasts. Abl does not mediate tyrosine phosphorylation of Stat3 and Shc, two important regulators of Src oncogenic activity. In contrast, Abl controls the activation of the small GTPase Rac for oncogenic signalling and active Rac partly rescued Src transformation in cells with inactive Abl. Moreover, Abl mediates Src-induced extracellular regulated kinase 5 (ERK5) activation to drive cell transformation. Finally, we find that Abl/Rac and Abl/ERK5 pathways also operate in human MCF7 and BT549 breast cancer cells, where neoplastic transformation depends on Src-like activities. Therefore, Abl is an important regulator of Src oncogenic activity both in mouse fibroblasts and in human cancer cells. Targeting these Abl-dependent signalling cascades may be of therapeutic value in breast cancers where Src-like function is important.
Introduction
The cytoplasmic tyrosine kinase Src plays important roles in signal transduction induced by a number of extracellular stimuli, including growth factors and integrins (Bromann et al., 2004) . Src regulates activated cell growth, survival and migration, and shows oncogenic activity when is deregulated. This was first shown with vSrc, an active and viral form of the cellular counterpart responsible for the oncogenic activity of the Rous sarcoma virus in chicken. Later, the middle T antigen of polyoma virus (mT) was shown to induce Src oncogenic activity in rodents. By associating with Src, the mT viral protein prevents phosphorylation of the negative regulatory tyrosine at the C terminus (Y527 in the chicken sequence) leading to constitutive kinase activity. Indeed, a kinase that harbours mutation of Tyr527 to Phe exhibits similar enzymatic and biological activities (Martin, 2001) . Elevated Src activity is found in human colon and breast cancers. How Src is activated during tumourigenesis is still an open question, since very few activating mutations have been reported. Instead, overexpression and/or protein stabilization may contribute to its deregulation, although alternative mechanisms can be expected (Yeatman, 2004) . A number of reports show a role of Src in tumour progression and metastasis (Ishizawar and Parsons, 2004) . Accordingly, Src has become a potential therapeutic target in these cancers with several pharmacological inhibitors in clinical trials (Chen et al., 2006) .
The molecular mechanism by which Src mediates cell transformation has been extensively studied in rodents, although not completely defined (Dilworth, 2002; Frame, 2004) . Src is thought to phosphorylate specific substrates that activate constitutive signalling required for cell transformation. For example, Src phosphorylates the adaptor Shc, leading to Grb2/SOS complex recruitment to the membrane and activation of the Ras pathway. However, active Src induces only a modest activation of the Ras effectors extracellular regulated kinases (ERK) 1 and 2 implicating additional pathways. Indeed, Src also phosphorylates Stat3 on Tyr705 and the regulatory p85 subunit of phosphoinositide 3 0 kinase (PI3K). Both Stat3 and PI3K activities are required for cell transformation. The small GTPase Rac of the Rho family has been also implicated in Src oncogenic signalling (Minden et al., 1995; Servitja et al., 2003) . It may function by activation of Jun N-terminal kinase (JNK) and p38 ERK, which phosphorylate the transcription factors Jun and Stat3 (Turkson et al., 1999) . Finally, ERK5 has been recently shown to participate in cell transformation via Src by an undefined mechanism (Barros and Marshall, 2005) .
Compelling evidence shows that the tyrosine kinase Abl is an important substrate for Src signalling in normal cells (Pendergast, 2002) . Abl resembles Src at its N terminus while its large C terminus has nuclear localization sequences and protein and DNA interaction domains. Interestingly, Abl function depends on its subcellular localization. Nuclear Abl regulates the cell response to DNA damage while cytoplasmic Abl participates in intracellular signalling induced by growth factors, cytokines and integrins (Lewis et al., 1996; Plattner et al., 1999; Furstoss et al., 2002; Daniels et al., 2004; Zipfel et al., 2004; Ushio-Fukai et al., 2005; Yang et al., 2006) . For example, the platelet derived growth factor (PDGF)-induced Abl activation is required for DNA synthesis and F-actin assembly (Furstoss et al., 2002) . Catalytic activity requires phosphorylation of Tyr245 and Tyr412 by Src (Hantschel and SupertiFurga, 2004) and this is necessary for morphological changes and mitogenesis (Furstoss et al., 2002) . Abl activity required for cytoskeleton rearrangement also implicates the phospholipase Cg (PLCg), albeit by an unknown mechanism (Plattner et al., 2003) . We and others have identified Rac as an important downstream component of Abl signalling, we have further shown that Abl mediates Src-induced c-myc expression and cell-cycle progression via Rac/JNK and Rac/NADPH oxidase signalling modules (Boureux et al., 2005) .
Like Src, Abl exhibits some oncogenic activity when it is deregulated. Active and cytoplasmic alleles induce rodent cell transformation, although not as efficiently as oncogenic Src (Zou and Calame, 1999) . Bcr-Abl oncoprotein is responsible for 95% of human chronic myeloid leukaemia. Indeed, the Abl inhibitor Imatinib is now largely used to treat this type of leukaemia (Krause and Van Etten, 2005) . Moreover, Abl might be involved in solid tumours, since Srinivasan and Plattner (2006) have reported elevated Abl and Arg activities in human breast cancer cells. This deregulation was dependent upon tyrosine kinases of the Src and the EGF receptor families that are implicated in mammary carcinoma. Abl deregulation may participate in cell invasion, as illustrated with the highly aggressive breast cell line MDAMB 435S. Abl was reported to regulate the epithelial to a mesenchyme transition of colon cancer cells induced by PDGF, which may involve Src (Yang et al., 2006) . Based on these data, we surmised that Abl may be an important Src substrate for oncogenic activity. Here we show that Abl is required for Srcinduced transformation of mouse fibroblasts, implicating both Rac and ERK5 for oncogenic signalling. Moreover, our data also implicate this signalling network in growth control of human breast cancer cells.
Results

Abl is required for Src-induced transformation of mouse fibroblasts
The contribution of Abl on the ability of Src to transform NIH 3T3 cells was first explored. To this end, we used the mT antigen for Src activation since the Src-mT complex has been found very efficient in foci induction (Dilworth, 2002) . SrcY527F exhibited lower biological activity in this assay, probably due to active protein degradation (not shown). Wild-type Src alone is regulated in fibroblasts and does not induce foci while mT coexpression strongly induced cell transformation ( Figure 1a ). As expected, this response was dependent on Src activity as transformation was strongly reduced by the Src-like inhibitor SU6656 or by expressing the SrcYF-K À inactive kinase (Figure 1b ). mT alone also induced foci in a Src-like dependent manner while not as efficiently as Src-mT coexpression (unpublished data). Interestingly, the Abl inhibitor Imatinib strongly affected foci formation. This effect was observed with an IC 50 of about 2.5 mM and a maximum of 10 mM. These data were consistent with the concentration range observed for inhibition of phosphorylated active Abl (Tanis et al., 2003) . Imatinib has been described to target c-Kit and PDGF receptors (Krause and Van Etten, 2005) , suggesting a role for these kinases during cell transformation. However, this was unlikely as AG-1296, a specific inhibitor of these receptors (Kovalenko et al., 1997) had no effect on Src transformation. Similarly, Imatinib had no effect on Src-induced phosphorylation in transformed cells and kinase activity of the Src-mT complex (Figures 1e and f) . A function of 
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A Sirvent et al Abl on Src transformation was next confirmed with dominant-negative approaches (Figure 1b) . Kinase dead Abl-K À strongly inhibited cell transformation unlike Abl. While not as active as Abl-K À , kinase inactive form of Arg, the other member of the Abl family, also reduced foci formation suggesting that it might be also implicated in Src-transforming activity. Similar results were obtained with Abl-PP mutants in which Pro242 and Pro249 were replaced with Glu. These mutations stabilize the kinase in an open conformation and target the protein in cell cytoplasm (Furstoss et al., 2002) .
These inhibitory effects suggested that the cytoplasmic pool of Abl was required for Src oncogenic activity. Indeed, a similar inhibition was obtained with Abl2YF-NLS À , in which nuclear localization signals and Src phosphorylation sites have been inactivated. Therefore, Tyr412 and Tyr245 are required for cytoplasmic signalling during Src transformation. The function of Abl was further confirmed with a siRNA approach. Downregulation of Abl also reduced Src-induced cell transformation ( Figure 1c) . Finally, the observed Abl function was not specific to the transformation assay or ip: 762 SU6656 Imatinib the cell type used as Imatinib also reduced anchorageindependent growth of vSrc-transformed Balbc 3T3 ( Figure 1d ). Previously, we reported that SrcY527F phosphorylates Abl required for kinase activation (Furstoss et al., 2002) . Whether the Src-mT complex activates Abl by a similar mechanism was then addressed (Figure 1e ). Expression of mT in HEK293 cells induced a large increase in cytoplasmic Abl activity concomitant with protein tyrosine phosphorylation. Both events were inhibited by the Src-like inhibitor SU6656 and mutation of Tyr245 and Tyr412 to Phe. This indicates that SrcmT-induced Abl activation requires phosphorylation on Tyr245 and Tyr412. Similar data were obtained in mTand SrcY527-transformed fibroblasts (Figure 1f ).
Abl does not mediate Shc and Stat3 tyrosine phosphorylation
Tyrosine phosphorylation of Stat3 and Shc regulate Srcinduced cell transformation (Bromberg et al., 1998; Nicholson et al., 2001) . Whether these phosphorylations require Abl in Src-transformed cells was next addressed. As shown in Figure 2a , Imatinib had no effect on Shc phosphorylation on Tyr239 and Tyr240 and Stat3 on Tyr705. Nevertheless, these phosphorylations were required for Src-mT-induced foci as shown by the inhibitory effects of Shc and Stat3 mutants in which these residues have been replaced by Phe (Shc2Y/2F and Stat3Y705F) (Figure 2b ). Tyr315 is another reported phosphorylation site of Shc required for Src-mTinduced foci (Nicholson et al., 2001) . However, Imatinib did not affect Shc tyrosine phosphorylation at all (Figure 2a) , suggesting that Abl does not phosphorylate this residue. We concluded that Src is the major kinase responsible for Stat3 and Shc tyrosine phosphorylation and that Abl regulates alternative signalling during cell transformation.
Abl regulates Rac activation for Src-induced transformation Whether Abl regulates Src-induced Rac activation was next addressed. SrcY527F increased Rac activity when expressed in HEK293 cells and this was inhibited by Imatinib treatment or expression of Abl-K À (Figure 3a ). These results were confirmed on the capacity of Rac to induce JNK activity. Indeed, Src also activated JNK in an Abl-dependent manner. Rac and JNK activities were also strongly increased in cells stably transformed by SrcY527F and inhibited by Imatinib treatment (Figure 3b ). The Abl inhibitor also reduced phosphorylation of JNK substrates in vivo as shown on Stat3-Ser727 and Jun-Ser63 phosphorylation. Therefore, Abl mediates Src-induced Rac signalling.
The biological impact of Rac on Abl signalling was next addressed. Several lines of evidence suggest that small GTPases of the Rho family were required for SrcmT to induce cell transformation (Urich et al., 1997; Servitja et al., 2003 and data not shown). The contribution of Rac was shown by reduction of cell transformation obtained with the dominant-negative RacN17 or Rac1-specific siRNA (Figure 3c ). It should be noticed that the siRNA strategy was less efficient than the dominant-negative approach while highly effective in Rac1 downregulation. This effect may be attributed to the temporary inhibition of the protein level during cell transformation assays (that is, 12 days) and/or the contribution of Rac3 that was not targeted by our siRNA. We next explored the role of Rac in Abl transforming signalling. As shown in Figure 3d 
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A Sirvent et al foci formation. Finally, the incidence of an Abl-JNK pathway was also evaluated on Src oncogenic activity (Figure 3f) . Surprisingly, none of JNK or p38 ERK activators gave a significant rescuing effect in cells with inactive Abl. We concluded that, while JNK activities are required for Src transformation, they are not sufficient for Abl signalling.
Abl regulates ERK5 activation for Src-induced transformation
We then sought additional pathways that contribute to Abl function. Expression of Abl-PP and a constitutive active form of the upstream kinase MKK5 in HEK293 cells induced a large increase in ERK5 activity (Figure 4a ). SrcY527F also induced ERK5 activation (Barros and Marshall, 2005), although not as strongly as Abl-PP. Interestingly, this response was inhibited by Imatinib treatment or expression of the kinase dead Abl-K À indicating that Abl mediates Src-induced ERK5 activity. Similarly, Imatinib treatment affected ERK5 activity that was largely increased in Src 527 fibroblasts (Figure 4b ). The role of Abl/ERK5 signalling was next addressed on Src-induced transformation (Figure 4c ). The dominant-negative ERK5AEF in which the activation phosphorylation sites have been replaced with non-phosphorylatable residues reduced Src-mT-induced foci. Conversely, forced expression of constitutive active ERK5 activator MKK5-DA fully restored Src-mT-transforming activity both in cells overexpressing inactive Abl and in cells treated with a sub-maximal dose of Imatinib (Figure 4d) . Therefore, ERK5 mediates Abl signalling required for Src transformation. Figure 5a , the specific Src-like inhibitor SU6656 reduced standard cell growth. This was observed in conditions where the inhibitor reduced Src activities by more than 50% (Figure 5b) . Whether Abl is a downstream element of Src function in these cells was next investigated. Src pharmacological inhibition induced a reduction of Abl activity by 50%. Imatinib induced a similar reduction on Abl activity and affected standard cell growth. This effect was linked to inhibition of Abl kinases as (i) related targets PDGF receptors or c-Kit were not detected in these cells (Srinivasan and Plattner, 2006) and (ii) AG-1296 had no effect on cell growth (Figure 6a) . Similarly, SU6656 and Imatinib strongly affected anchorage-independent cell growth, unlike AG-1296 (Figure 5c ). The specificity of this inhibition was also illustrated by the inability of these inhibitors to affect growth of the SKBR3 cell line that overexpresses ErbB2 (not shown). We concluded that a Src/Abl pathway may regulate transforming activities of these breast cancer cells in vitro.
To confirm oncogenic activities of these kinases, the role of Rac and ERK5 was analysed on neoplastic cell growth. First, we observed that Src and Abl regulate Rac1 activity as shown by the reduction of the GTPase active level in cells incubated with respective inhibitors (Figure 6a) . Abl inhibition had a lower impact suggesting that Src may activate additional pathways for Rac1 activation. Interestingly, pharmacological inhibition of Rac strongly reduced standard cell growth (Figure 6b ) in concordance with a role of Rac1 and Rac3 in BT549 cell growth (Chan et al., 2005) . Moreover, Rac inhibition also reduced anchorage-independent cell growth ( Figure 6e ) implicating Rac in their transforming activity. Similarly, we observed that Src and Abl kinases regulate ERK5 activity (Figure 6c ). Since no specific inhibitor is currently available, the role for ERK5 was evaluated by downregulating the kinase with a RNA interference approach (Figure 6d) (Garaude et al., 2006) . Cells were infected with retroviruses expressing shRNA specific to ERK5 that allows more than 50% reduction in both kinase activity and protein level. Under these conditions, a partial, but significant reduction of standard cell growth was observed and anchorageindependent cell growth was strongly reduced (Figure 6e ). We concluded that Rac and ERK5 are required for growth of MCF7 and BT549 cell lines. Additionally, these data reinforce the notion of an Src/ Abl signalling pathway involved in neoplastic transformation of breast cancer cells. In vitro kinase activity of the immunoprecipitated Abl was assessed using Gst-Crk as a substrate. Phosphorylation of Gst-Crk ( 32 P-Gst-Crk), levels of Abl and quantification of relative kinase activity are shown. In vitro kinase assay of immunoprecipitated SFK was assessed using denatured enolase as a substrate. Phosphorylation of enolase ( 32 P-Enolase), autophosphorylation of SFK ( 32 P-SFK), kinase levels and quantification of relative kinase activities are shown. (c) Imatinib and SU6656 reduce anchorage-independent cell growth. Indicated cells were seeded in soft-agar with 5 mM SU6656, 10 mM Imatinib, or vehicle (DMSO) as described in 'Materials and methods'. After 21 days, the number of colonies was scored and the mean7s.d. (n ¼ 3) is shown. *Po0.05 and **Po0.01 using a student's t-test. FCS, fetal calf serum; SFK, Src family kinases.
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Discussion
Abl plays an important role in Src signalling in normal cells and here we show that it is also required for Src oncogenic activity: Abl inhibition by pharmacological, dominant-negative or siRNA approaches, all reduced Src-induced foci. While Abl has a partial effect on cellcycle progression (not shown), its role in foci induction may primarily involve modulation of cell contactinduced growth inhibition. Additionally, Abl may also impact on anchorage-independent growth as illustrated in transformed mouse fibroblasts and human breast cancer cells. It should be mentioned that this tyrosine kinase has been reported as a negative regulator towards cell transformation (Suzuki et al., 2004) . This raises the idea that it may have positive or negative function depending on genetic background or the cell type used. For example, while the absence of Abl promoted SV40-induced cell growth, reintroduction of the corresponding gene accelerated cell growth after few passages.
Our report also shed new light on the Abl signalling pathways involved in Src-transforming activity. First, Figure 3d ). The existence of an Abl/Rac pathway is ascertained by the requirement of JNK in Src transformation. JNK signalling may implicate phosphorylation of Stat3 for maximal transcriptional activity (Turkson et al., 1999) . This means an Abl/Rac/JNK/Stat3 signalling cascade important for cell transformation. Nevertheless, the importance of this pathway has not been established since the role of Stat3-Ser727 has not been validated in Src transformation. Clearly additional Abl pathways are expected in this response. Accordingly, we have identified ERK5 as a novel Abl downstream component required for Src transformation. The pivotal role of ERK5 has been illustrated by the capacity of MKK5-DA to rescue transformation of cells with inactive Abl. How Abl impacts on ERK5 activation is not known but our data favour a mechanism implicating catalytic activation rather than protein stabilization as previously reported (Buschbeck et al., 2005) . Abl may probably interact with upstream kinases, alternatively Abl-induced ERK5 may implicate Rac. Recent reports suggest that ERK5 participates in Src-induced cytoskeleton rearrangement (Barros and Marshall, 2005) , Jun and cyclin D induction required for cell-cycle progression (Kato et al., 1997; Mulloy et al., 2003) and NF-kB activation leading to cell survival (Garaude et al., 2006) . Probably all these effects may contribute to Src-transforming activity. Our study also suggests that Abl plays a functional role in breast cancer progression. This notion is in agreement with inhibitory effects observed with Imatinib in some breast cancer cells (Roussidis et al., 2004; Srinivasan and Plattner, 2006) . Pharmacological inhibition did not correlate with expression of related targets implicating an Abl-like activity in neoplastic cell transformation. This has been further confirmed in MDAMB 435S cells by downregulation of Abl level with an siRNA approach (Srinivasan and Plattner, 2006) . Therefore, Abl inhibition may be of therapeutic value in mammary carcinoma. In this regard, a preclinical study reported preferential sensitivity to the dual Src/Abl inhibitor Dasatinib for breast cancer cells of basal-type scored negative for ErbB2 and that have undergone the epithelial to a mesenchymal transition (Finn et al., 2007) . We also noticed that while a high dose of Imatinib gave significant inhibitory effect on cell growth, it only gave a partial reduction on Abl activity in vitro. This may be explained by the low affinity of the inhibitor for phosphorylated and active form of the kinase (Tanis et al., 2003) . Inhibitors that efficiently inhibit activated Abl may be of better therapeutic value. This notion has been recently validated with inhibitors of the EGF receptor family and suggests that a lack of efficient catalytic inhibition is sufficient to induce therapy failure (Sergina et al., 2007) . Finally, our study also shows that an Src/Abl/Rac/ERK5 operates in breast cancer cells. This notion is illustrated with the inhibitory effect observed with Rac and ERK5 inactivation. Therefore, targeting this signalling pathway may be a therapeutic benefit to treat this cancer.
with 10% fetal calf serum (FCS). BT549 and MCF7 were maintained respectively in DMEM F12 and RPMI supplemented with 10% FCS. Cell culture, transfections and retroviral infections were described previously . For drug treatment, cells were treated with the indicated inhibitor (or DMSO as a vehicle) for 5 h in growth medium supplemented with 1% FCS. siRNA duplexes (25 nM) targeting mouse Abl (Dharmacon, Lafayette, CO, USA), Rac1 (Deroanne et al., 2003) and controls (Scramble) were transfected using calcium phosphate as described in Boureux et al. (2005) . Knockdown of Rac1 expression was done using specific siRNA as described in Deroanne et al. (2003) . EKR5 downregulation was obtained by infection of wild-type (mock) or shRNA ERK5 expressing retroviruses (Garaude et al., 2006) .
Cell growth and transforming assays
Standard cell growth was performed in 2% FCS medium using 24-well plates (50 000 cells/well) and measured by sulforhodamide B staining according to manufacturer's instructions (Sigma Aldrich). Focus formation was performed using NIH 3T3 cells transfected with indicated construct using Lipofect-AMINE reagent (Invitrogen, Cergy, France) and maintained in 10% FCS for 12-14 days. After staining with crystal violet (1%), foci larger than 0.5 mm in diameter were visually scored. For anchorage-independent cell growth, 0.67% agar in medium was layered on the bottom of a 12-well plate and 1000 (vSrc-3T3), 2000 (MCF7) or 4000 (BT549) cells/well were seeded on the top of this layer in 0.33% agar medium. After 18-21 days colonies having >50 cells were scored positive. Inhibitors or vehicle (DMSO) were added every 3 days.
Biochemistry
Cell lysate, immunoprecipitation, Rac1 pull-down and western blotting were performed as previously described (Boureux et al., 2005; Veracini et al., 2006) . In vitro kinase assays for SFK, Abl, ERK5 and JNK were described in Boureux et al. (2005) , Kayahara et al. (2005) and Veracini et al. (2006) .
